KalaGhazi | Corvus Pharmaceuticals

NASDAQ:CRVS   Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Extends Gains in Premarket Thursday After Reporting 'Strong Progress' in Immune Diseases Treatment
On Wednesday, the company said it will present new data for CPI-818 at the International Conference on Malignant Lymphoma meeting in Lugano, Switzerland from June 13 to 17.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.